The management of HIV-infected pregnant women

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 6, 2012, Pages 395-401

  Senise, Jorge ^a   Bonafé, Simone ^a   Castelo, Adauto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antiretroviral therapy; HIV; pregnancy; vertical transmission

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CHORIOAMNIONITIS; CONGENITAL MALFORMATION; CYTOMEGALOVIRUS INFECTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; ELECTIVE SURGERY; EVIDENCE BASED MEDICINE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LACTIC ACIDOSIS; LIMIT OF DETECTION; LIVER TOXICITY; META ANALYSIS (TOPIC); MONOTHERAPY; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; PROLONGED PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYPHILIS; TOXIC HEPATITIS; TOXOPLASMOSIS; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; DELIVERY, OBSTETRIC; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 84870153489     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328359f11e     Document Type: Review

References (70)

1. UNAIDS. World AIDS Day Report 2011. http://www.unaids.org/en/media/ unaids/contentassets/documents/unaidspublication/2011/JC2216-World AIDSday-report-2011-en.pdf. [Accessed 12 March 2012].
2. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 1999; 13:407-414. (Pubitemid 29095104)
3. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340:585-588.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
5. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-393. (Pubitemid 29362511)
6. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:724-732.
7. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-252.
8. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-tochild transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 200-2006. AIDS 2008; 22:973-981. (Pubitemid 351652248)
9. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-299.
10. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2012. http://www.aidsinfo. nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. [Accessed 7th August 2012].
11. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women. HIV Med 2012; 13 (Suppl. 2):87-157.
12. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
13. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
14. Read PJ, Mandalia S, Khan P, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26:1095-1103.
15. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005; 38:87-95. (Pubitemid 40094125)
16. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads (Pubitemid 32147509)
17. Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367) [abstract]. In: abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2004.
18. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78::58-59. (Pubitemid 34206317)
19. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17:272-273. (Pubitemid 36183059)
20. Antiretroviral pregnancy international registry interim report. 2012. http://www.apregistry.com/forms/exec-summary.pdf. [Accessed 17 July 2012].
21. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-1159.
22. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16:1149-1167.
23. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr 2007; 44:371-376. (Pubitemid 46555370)
24. McIntyre JA. Controversies in the use of nevirapine for prevention of motherto-child transmission of HIV. Expert Opin Pharmacother 2006; 7:677-685.
25. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care 2005; 17:17.
26. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24:1461-1470.
27. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25:2301-2304.
28. Bera E, McCausland K, Nonkwelo R, et al. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS 2010; 24:283-289.
29. Knapp KM, Brogly SB,Muenz DG, et al. Prevalence of congenital anomalies in infants with inutero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31:164-170.
30. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16:299-300. (Pubitemid 34118582)
31. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25:555-556. (Pubitemid 41122407)
32. FDA. Important information about Sustiva (efavirenz) and pregnancy. 2005. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVand AIDSActivities/ucm124885.htm. [Accessed 17 July 2012].
33. WHO. The global action report on preterm birth. 2012. http://www.who. int/pmnch/media/news/2012/201204-borntoosoon-countryranking.pdf. [Accessed 19 July 2012].
34. European Collaborative study; Swiss Mother and Child HIVCS Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-2920.
35. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348-1360.
36. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-514.
37. Azria E, Moutafoff C, Schmitz T, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther 2009; 14:423-432.
38. Senise J, Cruz R, Palacios R, et al. Low-birth weight and preterm delivery in relation to lopinavir/ritonavir use in pregnancy. Am J Infec Dis 2008; 4:209-214.
39. Aebi-Popp K, Lapaire O, Glass TR, et al. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. J Perinat Med 2010; 38:353-358.
40. Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can 2012; 34:136-141.
41. von Hentig N, Nisius G, Lennemann T, et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1000/100mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther 2008; 13:1039-1046.
42. Martinez-Rebollar M, Lonca M, Perez I, et al. Pharmacokinetic study of saquinavir 500mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Ther Drug Monit 2011; 33:772-777.
43. van der Lugt J, Colbers A, Molto J, et al. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther 2009; 14:443-450.
44. Hanlon M, O'Dea S, Clarke S, Mulcahy F. Maternal hepatotoxicity with boosted saquinivir as part of combination ART in pregnancy [abstract]. In: abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles; 2007.
45. Roberts SS, Martinez M, Covington DL, et al. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr 2009; 51:456-461.
46. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939. (Pubitemid 44427610)
47. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49:485-491.
48. Bouillon-Pichault M, Jullien V, Azria E, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother 2009; 63:1223-1232.
49. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 2011; 25:1299-1303.
50. EACS. AIDS Guidelines. 2011. http://www.europeanaidsclinicalsociety.org/ images/stories/EACS-Pdf/eacsguidelines-v6-english.pdf. [Accessed 3 July 2012]
51. FDA notifications. FDA approves new atazanavir labeling. AIDS Alert 2011; 26:33-34.
52. Esker S, Albano J, Uy J, et al. Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy. AIDS Patient Care STDS 2012; 26:307-311.
53. Ivanovic J, Bellagamba R, Nicastri E, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24:1083-1084.
54. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol 2011; 157:18-21.
55. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011; 12:570-579.
56. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56:412-419.
57. Meyohas MC, Lacombe K, Carbonne B, et al. Enfuvirtide prescription at the end of pregnancy to a multitreated HIV-infected woman with virological breakthrough. AIDS 2004; 18:1966-1968. (Pubitemid 39313217)
58. Wensing AM, Boucher CA, van Kasteren M, et al. Prevention of mother-tochild transmission of multidrug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 2006; 20:1465-1467. (Pubitemid 43948260)
59. Jeantils V, Alloui C, Rodrigues A, et al. [Use of enfurvitide in pregnancy in HIV positive women in seven cases]. Gynecol Obstet Fertil 2009; 37:396-400.
60. Madeddu G, Calia GM, Campus ML, et al. Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy. Int J STD AIDS 2008; 19:644-645.
61. Weizsaecker K, Kurowski M, Hoffmeister B, et al. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS 2011; 22:294-295.
62. Ceccaldi PF, Ferreira C, Gavard L, et al. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198:433.
63. Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 2006; 20:297-299.
64. McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010; 24:2416-2418.
65. Croci L, Trezzi M, Allegri MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol 2012; 68:1231-1232.
66. Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS 2011; 22:358-360.
67. Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010; 65:2050-2052.
68. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-987.
69. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280:55-60. (Pubitemid 28414997)
70. European Collaborative S, Boer K, England K, et al. Mode of delivery in HIVinfected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11:368-378.